Blockchain Registration Transaction Record

HighTide's HTD1801 Shows Renoprotective Potential at ERA Congress

HighTide Therapeutics presents new renoprotective data for HTD1801 at ERA 2026, showing improved renal function in T2DM patients and mechanistic insights in podocyte injury models.

This news matters because chronic kidney disease (CKD) affects millions worldwide, often progressing to end-stage renal disease with limited treatment options. HTD1801's dual mechanism targeting inflammation and metabolism could offer a new disease-modifying therapy, potentially slowing CKD progression and reducing the burden on patients and healthcare systems. The positive clinical and preclinical data suggest a promising future for managing CKM diseases holistically.